Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET
Company Participants
Sujal Patel - Co-Founder and CEO
Parag Mallick - Co-Founder and Chief Scientist
Anna Mowry - CFO
Conference Call Participants
Max Masucci - Cowen
David Delahunt - Goldman Sachs
Brandon Couillard - Jefferies
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Nautilus Q3 2022 Earnings Call. [Operator Instructions]
I would now like to turn the call over to your host [Alex Khan], Investor Relations. You may begin.
Unidentified Company Representative
Thank you. Earlier today, Nautilus released its financial results for the quarter ended September 30, 2022. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to investorrelations@nautilus.bio.
Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.
Before we begin, I would like to remind you that management will make statements today during this call that are forward looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled Forward-Looking Statements in the press release of Nautilus issued today.
Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, November 1, 2022.
With that, I'll turn the call over to Sujal.
Sujal Patel
Thanks Alex. Good morning, and thank you to everyone for joining us today.
On this call, we'll share our results for the third quarter of 2022 and provide some insight on the expected value of our platform, our progress towards commercialization and a quick observation on the market landscape, but first, I want to thank our growing teams in the Bay Area and Seattle for their focus on short-term development milestones and longer-term commercialization goals.
Their efforts continue to yield results that get us ever closer to our ultimate purpose of improving the lives and health of people around the world. Our entire team is fully aligned towards and committed to realizing this important objective.